Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥132 | ¥139 | ¥93 | ¥135 |
| - Cash | ¥45 | ¥30 | ¥24 | ¥33 |
| + Debt | ¥232 | ¥202 | ¥173 | ¥144 |
| Enterprise Value | ¥319 | ¥312 | ¥242 | ¥247 |
| Revenue | ¥260 | ¥228 | ¥209 | ¥166 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Gross Profit | ¥95 | ¥81 | ¥73 | ¥70 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| EBITDA | ¥48 | ¥36 | ¥25 | ¥29 |
| % Margin | 18.5% | 15.6% | 12% | 17.8% |
| Net Income | ¥19 | ¥16 | ¥2 | ¥16 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS Diluted | 385.7 | 328.58 | 44.72 | 316.19 |
| % Growth | 17.4% | 634.7% | -85.9% | – |
| Operating Cash Flow | ¥23 | ¥8 | ¥3 | ¥22 |
| Capital Expenditures | -¥29 | -¥39 | -¥30 | -¥14 |
| Free Cash Flow | -¥5 | -¥31 | -¥28 | ¥9 |